Clinical trials: Infusion Rates
Healthy Volunteers
A Study of TAK-881 in Healthy Adults
The main aims of this study are to check for side effects from TAK-881 in healthy adults and to learn how much TAK-881 they can receive without getting side effects from it.
- Trial name
- NCT05059977
- Testing
- TAK-881
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Takeda
Healthy
Comparison of the Effect on the Glucose Infusion Rates Between Inhaled Technosphere Insulin and a Subcutaneous Injection of Regular Human Insulin
A prospective, single center, open randomized, six way crossover study comparing the dose response effect of four different doses of Technosphere Insulin after pulmonary function delivery in comparison to s.c.
- Trial name
- NCT00511979
- Testing
- Technosphere Insulin, Regular human insulin
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Mannkind Corporation
Healthy Volunteers
A Study of Sterile Saline Infusion in Healthy Volunteers
The purpose of the study is to evaluate the influence of needle size, injected fluid volume, and rate of fluid on the degree of pain experienced by adult healthy volunteers after subcutaneous infusion of sterile saline.
- Trial name
- NCT06194578
- Testing
- Sterile Saline
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy
An Exploratory Study of LPM3480392 at Different Infusion Rates in Chinese Healthy Subjects
This study evaluated the safety, tolerability and PK/PD characteristics of LPM3480392 injection by intravenous infusion at different rates in healthy subjects.The experiment was divided into Part A and Part B.
- Trial name
- NCT05857449
- Testing
- LPM3480392
- Where
- China
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Healthy, Pharmacokinetics of Mirabegron
Pharmacokinetics of Oral Mirabegron With Different Release Rates Versus Intravenous (IV) Mirabegron
The purpose of this study is to assess the pharmacokinetics of three doses of oral mirabegron formulations with three different release rates versus three doses of mirabegron administered intravenously; to study safety and side…
- Trial name
- NCT00940121
- Testing
- mirabegron
- Where
- United States
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
Alpha1 Antitrypsin Deficiency, Alpha1-Proteinase Inhibitor Deficiency
Phase 4, Double-blind Study Evaluating the Response on Computed Tomography (CT) Lung Density Decline Rates of Respreeza / Zemaira Weekly for 3 Years in Adults With alpha1 Antitrypsin Deficiency (AATD)
This is a multicenter, parallel-group, double-blind, randomized phase 4 study designed to identify the optimal dose of CE1226 (2 active doses) to slow disease progression as assessed by reduced rates of annual lung density…
- Conditions
- Alpha1 Antitrypsin Deficiency, Alpha1-Proteinase Inhibitor Deficiency, Emphysema
- Trial name
- NCT07326592
- Testing
- CE1226
- Where
- 2 sites in Denmark
- Volunteers
- 270 people
- Sponsor
- CSL Behring
Healthy
A Study to Evaluate Lu AF90103 in Healthy Men
The purpose of this study is to investigate the safety and tolerability of Lu AF90103 and what the body does to Lu AF90103 after single doses of the drug administered directly into a vein.
- Trial name
- NCT04940949
- Testing
- Lu AF90103
- Where
- Netherlands
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Peripheral Vascular Disease
Study of Safety and Tolerability of UNIFUZOL (Solution for Infusions) in Healthy Volunteers
Unifusol (R) is a solution of arginine sodium succinate for intravenous infusions. Its effects include vasodilation, protection of inner layer of blood vessels and improvement of blood viscosity.
- Trial name
- NCT03028285
- Testing
- arginine sodium succinate
- Where
- 2 sites in Russia
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- POLYSAN Scientific & Technological Pharmaceutical Company
Primary Immunodeficiency Disease
High Infusion Rate Study of Immunoglobulin Intravenous (Human) 10% (NewGam)
This was a prospective, open-label, non-controlled, non-randomized multicenter Phase III study of 2 multiple-dose intravenous NewGam regimens (every 3 weeks or every 4 weeks, continuing the patient's infusion interval in the main…
- Trial name
- NGAM-05 (NCT01313507)
- Testing
- NewGam
- Where
- 6 sites in United States
- Volunteers
- 21 people
- Sponsor
- Octapharma
Healthy
A Study of ARC-520 at Varying Infusion Rates in Healthy Adult Volunteers
Single doses of ARC-520 will be evaluated at varying infusion rates and by slow bolus push.
- Trial name
- NCT02535416
- Testing
- ARC-520, cetirizine, diphenhydramine
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Arrowhead Pharmaceuticals
Purpura, Thrombocytopenic, Idiopathic
Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP
The objective of this study is to determine if the safety and tolerability of Immune Globulin Intravenous (Human), 10% Caprylate/Chromatograph Purified (IGIV-C) is similar when infused at two different infusion rates.
- Trial name
- NCT00220727
- Testing
- Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Grifols Therapeutics LLC
Congenital Hyperinsulinism
CSI-Glucagon for Prevention of Hypoglycemia in Children With Congenital Hyperinsulinism
This is a Phase 2, multi-center, randomized, placebo-controlled, double-blind trial with open-label follow-up designed to assess the efficacy of Xeris Glucagon delivered as a continuous subcutaneous infusion to prevent…
- Trial name
- NCT02937558
- Testing
- Glucagon
- Where
- 5 sites in United States
- Volunteers
- 5 people
- Sponsor
- Xeris Pharmaceuticals
Determine If Adherence Rates with IV Antibiotics in OPAT Have a Correlation to Hospital Readmission Rates
IV Ensure in Patients Receiving OPAT
The purpose of remote therapeutic monitoring is to provide oversight and evaluation of patients receiving IV medications in the home setting post-acute.
- Trial name
- NCT06623318
- Testing
- Remote therapeutic monitoring device
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- IV Ensure
Healthy
A Study to Evaluate the Use of a Graded Infusion of Intravenous Glucose in the Assessment of Insulin Secretion Rates (MK-0000-078)
A two period pilot study to determine if a graded glucose infusion using a glucose (20% dextrose [D20]) intravenous infusion can be properly implemented and will be well tolerated in healthy subjects.
- Trial name
- NCT01021462
- Testing
- Comparator: graded infusion of intravenous glucose
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Rheumatoid Arthritis
A Study Comparing Infusion Rates of Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis
This 2 arm study will compare the incidence of tocilizumab-related infusion reactions, using 2 different infusion times, in patients with moderate to severe rheumatoid arthritis who have shown an inadequate response to DMARDs…
- Trial name
- NCT00887341
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- 24 sites in Spain
- Volunteers
- 76 people
- Sponsor
- Hoffmann-La Roche
Intraosseous Access, Infusion Rates
Infusion Flow Rates and Blood Sampling
To evaluate infusion flow rates attainable when using the proximal humerus and proximal tibia IO vascular access sites. To evaluate the intraosseous infusion physiology when using the proximal humerus and proximal tibia IO…
- Conditions
- Intraosseous Access, Infusion Rates, Intraosseous Blood, Venous Blood
- Trial name
- NCT02021617
- Testing
- Intraosseous access
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Vidacare Corporation
Hemophilia A or B With Inhibitors
FEIBA Reconstitution Volume Reduction and Faster Infusion Study (FEIBA STAR)
The purpose of this study is to: 1. To evaluate the tolerability and safety of infusing reduced volume Factor Eight Inhibitor Bypassing Activity (FEIBA) at the standard infusion rate of 2 U/kg/min 2.
- Trial name
- NCT02764489
- Testing
- FEIBA
- Where
- 3 sites in Croatia, North Macedonia and 1 more
- Volunteers
- 45 people
- Sponsor
- Baxalta now part of Shire
Healthy
A Study to Assess the Effects of Exenatide on Insulin Secretion Rates Using a Graded Infusion of Intravenous Glucose (0000-099)(COMPLETED)
A four-period study to evaluate if the grade glucose infusion procedure will be able to detect an increase in beta-cell glucose sensitivity from exenatide compared to no treatment in healthy subjects.
- Trial name
- NCT01021527
- Testing
- Comparator: Treatment A, Comparator: Treatment B, Comparator: Treatment C
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC